BiotechTube
Gradientech

Gradientech

Gothenburg, Sweden· Est.
gradientech.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11M

Overview

Gradientech is a commercial-stage diagnostics company addressing the critical need for faster antibiotic susceptibility testing, particularly in sepsis management. Its flagship product, the QuickMIC® system, leverages a proprietary microfluidics and live imaging platform to generate phenotypic MIC results with high precision in 2-4 hours, dramatically faster than traditional methods. The system is CE-marked for its Gram-negative panel in Europe and holds Breakthrough Device designation from the U.S. FDA, positioning it for significant impact in combating antimicrobial resistance and improving patient outcomes. The company is actively presenting data at major scientific conferences and expanding its commercial footprint.

SepsisInfectious Diseases

Technology Platform

Proprietary microfluidics platform combining linear antibiotic concentration gradients with real-time live cell imaging to perform rapid phenotypic antibiotic susceptibility testing (AST).

Funding History

2
Total raised:$11M
Series A$8.5M
Seed$2.5M

Opportunities

The global rise of antimicrobial resistance (AMR) and the high mortality rate of sepsis create a massive, urgent need for faster diagnostic tools.
QuickMIC's ability to deliver gold-standard MIC results in 2-4 hours positions it to improve antibiotic stewardship and patient outcomes, driving adoption in hospital labs.
FDA Breakthrough Device designation and potential future panel expansions (e.g., Gram-positive, fungi) represent significant growth avenues.

Risk Factors

Key risks include regulatory uncertainty, particularly in obtaining FDA 510(k) clearance for the U.S.
market.
The company faces intense competition from large, established diagnostics corporations and must prove cost-effectiveness to secure hospital adoption.
As a private, early-revenue company, it also faces execution and financing risks to fund commercial expansion and R&D.

Competitive Landscape

Gradientech competes in the automated AST market against large players like bioMérieux (VITEK), BD (Phoenix), and Beckman Coulter (MicroScan). It differentiates by offering phenotypic MIC results in 2-4 hours, faster than these traditional systems. It also competes with rapid genotypic/phenotypic combo tests (e.g., Accelerate PhenoTest) and must demonstrate superior precision (via linear gradients) and workflow advantages to gain market share.

More companies in Sweden →